CRINETICS PHARMACEUTICALS is a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. CRINETICS PHARMACEUTICALS is based in SAN DIEGO.
| Revenue (Most Recent Fiscal Year) | $7.70M |
| Net Income (Most Recent Fiscal Year) | $-465.32M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 214.74 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.03 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -2746.18% |
| Net Margin (Trailing 12 Months) | -2747.18% |
| Return on Equity (Trailing 12 Months) | -43.96% |
| Return on Assets (Trailing 12 Months) | -39.61% |
| Current Ratio (Most Recent Fiscal Quarter) | 18.60 |
| Quick Ratio (Most Recent Fiscal Quarter) | 18.56 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 1.00 |
| Book Value per Share (Most Recent Fiscal Quarter) | $12.15 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-1.23 |
| Earnings per Share (Most Recent Fiscal Year) | $-4.95 |
| Diluted Earnings per Share (Trailing 12 Months) | $-5.13 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 105.44M |
| Free Float | 101.43M |
| Market Capitalization | $3.88B |
| Average Volume (Last 20 Days) | 1.42M |
| Beta (Past 60 Months) | 0.28 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 3.80% |
| Percentage Held By Institutions (Latest 13F Reports) | 98.51% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |